What makes broadly neutralizing HIV antibodies work
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy
This project examines blood and tissue samples from people with HIV who received broadly neutralizing antibodies to find immune and viral patterns linked to longer control after stopping ART.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11330339 on NIH RePORTER |
What this research studies
Researchers will analyze stored blood and tissue samples from people with HIV who received broadly neutralizing antibodies while on ART, using advanced multi-omics tests such as single-cell CITE-seq and chromatin profiling. They will compare people who maintained viral control after stopping ART to those who had quick rebound to find immune and viral signatures associated with longer control. The team will integrate virologic, immunologic, and genomic data from the T003 clinical specimens and related animal data to test whether antibodies directly target the reservoir or boost cellular immunity. Findings will be used to guide how antibody-based approaches are optimized in future cure strategies.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV who were ART-suppressed and received broadly neutralizing antibodies in clinical protocols or who might be eligible for future bNAb trials.
Not a fit: People without HIV or those who are not candidates for bNAb treatment are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could help design better antibody-based approaches that prolong HIV control and reduce the need for continuous ART.
How similar studies have performed: Previous bNAb trials and animal studies have shown delayed viral rebound in some cases, but the precise mechanisms behind those successes remain unclear.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Barouch, Dan H. — Beth Israel Deaconess Medical Center
- Study coordinator: Barouch, Dan H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.